Kortide

Kortide is a clinical-stage biotechnology company specializing in the discovery and development of innovative peptide therapeutics. The company utilizes its proprietary peptide drug discovery platform to identify and optimize lead candidates for metabolic diseases, oncology, and inflammatory disorders. Kortide's lead program, KT-001, is a long-acting GLP-1/GIP dual receptor agonist currently in clinical development for the treatment of obesity and type 2 diabetes. Headquartered in Suzhou, China, the company is focused on leveraging advanced peptide engineering to create highly potent and selective therapies with improved safety profiles. By integrating computational design with high-throughput screening, Kortide aims to accelerate the delivery of next-generation treatments to patients worldwide.